Nifekalant
drugOn this page
Also known as Nifekalant hydrochlorideSID26758059SID174007049
Summary
Nifekalant (CHEMBL360861) is a phase-3 clinical-stage small molecule; indicated across 1 condition including atrial fibrillation.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 1 condition
- Clinical trials: 4
- Chemistry: 405.4 Da · C19H27N5O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL360861 |
| Name | Nifekalant |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 4486 |
| Molecular formula | C19H27N5O5 |
| Molecular weight | 405.4 |
| InChIKey | OEBPANQZQGQPHF-UHFFFAOYSA-N |
SMILES: CN1C(=CC(=O)N(C1=O)C)NCCN(CCCC2=CC=C(C=C2)[N+](=O)[O-])CCO
IUPAC name: 6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione
Also known as: Nifekalant, Nifekalant hydrochloride, SID26758059, nifekalant, SID174007049, NIFEKALANT, NIFEKALANT HYDROCHLORIDE
Parent form; salt/anhydrous children: CHEMBL553090
Patent coverage: 173 distinct patent families (568 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Solute carrier family 22 member 2, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Beta-1 adrenergic receptor, Sodium-dependent serotonin transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Prostaglandin G/H synthase 1.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| KCNH2 | 6.24 | AC50 | 570 | nM | CHEMBL_ACT_25118806 |
| SLC47A1 | 6.19 | IC50 | 650 | nM | CHEMBL_ACT_12636122 |
| SLC47A1 | 5.96 | IC50 | 1100 | nM | CHEMBL_ACT_12636131 |
| SLC47A2 | 5.57 | IC50 | 2700 | nM | CHEMBL_ACT_12636209 |
| SLC47A2 | 5.19 | IC50 | 6500 | nM | CHEMBL_ACT_12636140 |
| SLC47A1 | 5.19 | IC50 | 6500 | nM | CHEMBL_ACT_12637810 |
| KCNH2 | 5 | IC50 | 10000 | nM | CHEMBL_ACT_1449640 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03855826 | PHASE4 | UNKNOWN | Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection. |
| NCT04209959 | PHASE4 | UNKNOWN | Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation |
| NCT05169866 | PHASE3 | RECRUITING | Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery |
| NCT03853369 | Not specified | UNKNOWN | Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: atrial fibrillation